Aletta May Soon Be Automatically Collecting Human Blood for Testing

Aletta could make blood collection a scalable healthcare-automation opportunity, but its commercial success depends on reliability, patient acceptance and whether labour savings exceed equipment and servicing costs.

• Vitestro's platform received US FDA authorisation in August 2026 for supervised use in adults in outpatient settings, using near-infrared imaging, ultrasound and robotics to perform the draw and apply a bandage.
• A study of 1,633 patients found a 94.5% first-attempt success rate when a suitable vein was identified, including 92.7% among patients reporting difficult vein access; 90% reported pain similar to or less than manual collection.
• One trained phlebotomist could oversee up to three machines, potentially increasing capacity, although staff must still supervise procedures and check tubes.
• Vitestro raised $70 million in March from investors including Labcorp Venture Fund, Mayo Clinic, Sutter Health and Intuitive Surgical cofounder Fred Moll, bringing laboratory, clinical and robotics expertise.
• FDA authorisation does not imply immediate availability: Vitestro still needs manufacturing and commercial infrastructure, plans a US multicentre trial and must provide further evidence on sample quality and performance across patient groups.

Takeaway: Aletta targets a frequent, labour-intensive procedure with measurable costs, but investors should wait for deployment evidence showing that reliability, patient acceptance and operating savings justify the capital and servicing expense.